3rd Annual MSK Symposium on Lymphoma
State-of-the-Art in Biology, Therapy and Patient Care

MAY 11-12, 2018 | NEW YORK CITY
This symposium will feature updated information on lymphoma biology, diagnosis, immunology, and genetics, and ongoing efforts to translate the scientific discoveries into novel treatment strategies for a variety of lymphomas. Faculty will review the current standard of care and present their own perspectives on how they treat various types of lymphomas. Participants will have the opportunity to discuss diagnostic and management cases, and how to incorporate biologic and genetic biomarkers into clinical practice and clinical trials.

EDUCATIONAL OBJECTIVES
• To provide up-to-date information on recent molecular diagnostic methods
• To provide up-to-date information on recent update on lymphoma pathology classification
• To provide up-to-date information on recent treatment options for patients with Hodgkin and non-Hodgkin lymphoma

TARGET AUDIENCE
The target audience includes medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in diagnosis, treatment, and biomedical research of lymphoma.
INVITED FACULTY

Ash A. Alizadeh, MD, PhD
Stanford University
Stanford, CA

Marc André, MD
Université Catholique de Louvain
Belgium

Stephen M Ansell, MD, PhD
Mayo Clinic
Rochester, Minnesota

Andreas Engert, MD
University Hospital of Cologne
Germany

Jude Fitzgibbon, PhD
Barts Cancer Institute
England

John P. Leonard, MD
Weill Cornell Medical College
New York, NY

Ronald Levy, MD
Stanford University
Stanford, CA

David Maloney, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA

Ari M. Melnick, MD
Weill Cornell Medical College
New York, NY

Franck Morschhauser, MD
Centre Hospitalier Régional Universitaire de Lille
France

Sattva S. Neelapu, MD
MD Anderson Cancer Center
Houston, Texas

Featuring National and International Experts

Laura Pasqualucci, MD
Columbia University
New York, NY

Davide Rossi, MD, PhD
The Institute of Oncology Research
Switzerland

Stephen J. Schuster, MD
The University of Pennsylvania
Philadelphia, PA

John Seymour, MBBS, FRACP, PhD
Peter MacCallum Cancer Centre
Australia

Louis M. Staudt, MD, PhD
National Cancer Institute
Bethesda, MD

Catherine Thieblemont, MD
Saint-Louis Hospital
France

Irving Weissman, MD
Stanford University
Stanford, CA

Wyndham Wilson, MD, PhD
National Cancer Institute
Bethesda, MD

Thomas E. Witzig, MD
Mayo Clinic
Rochester, Minnesota

Weili Zhao, MD, PhD
Shanghai Institute of Hematology
China

SCIENTIFIC AGENDA

FRIDAY, MAY 11, 2018

7:30 AM  REGISTRATION & BREAKFAST

8:00 AM  Department of Medicine Grand Rounds
Disrupting the CD47-SIRPα Anti-phagocytic Axis to Treat Cancer
Irving Weissman, MD

9:00 AM  State of the Lymphoma at Memorial Sloan Kettering
Anna Younes, MD

SESSION I
Advances and State of the Art in Clinical Care-1
MODERATOR  Andrew D. Zelenetz, MD, PhD

9:45 AM  Diffuse Large B Cell Lymphoma (DLBCL)
Andrew D. Zelenetz, MD, PhD

10:00 AM  T Cell Lymphoma
Steven M. Horwitz, MD

10:15 AM  Mantle Cell Lymphoma
John P. Leonard, MD

10:30 AM  MCL Trials at MSKCC
Anita Kumar, MD

10:45 AM  HIV Lymphoma
Ariela Noy, MD

11:00 AM  Panel Discussion
Session I Faculty
& John P. Leonard, MD

11:30 AM  BREAK

SESSION II
Advances and State of the Art in Clinical Care-2
MODERATOR  Craig H. Moskowitz, MD

11:45 AM  Follicular Lymphoma (FL)
John Seymour, MBBS, FRACP, PhD

12:00 PM  Hodgkin Lymphoma (HL)
Andreas Engert, MD

12:15 PM  HL Trials at MSKCC
Alison J. Moskowitz, MD

12:30 PM  Marginal Zone Lymphoma
Catherine Thieblemont, MD

12:45 PM  Double Hit Lymphoma
Wyndham Wilson, MD, PhD

1:00 PM  Panel Discussion
Session II Faculty
& Marc André, MD

1:30 PM  LUNCH

Adult BMT Luncheon (1:30-2:15 PM)*
Are CARs Over Taking Transplant in Lymphoma

*Space is limited and RSVP is required during course registration.
SCIENTIFIC AGENDA

SESSION III
Biology
MODERATOR Hans-Guido Wendel, MD
2:30 pm Identifying New Therapeutic Targets in Follicular Lymphoma
Hans-Guido Wendel, MD
2:45 pm Mechanism-based Therapy of DLBCL
Louis M. Staudt, MD, PhD
3:00 pm Epigenetic Evolution in Lymphoma
Ari M. Melnick, MD
3:15 pm Genetic Landscape of Follicular Lymphoma
Jude Fitzgibbon, PhD
3:30 pm Genetic Cooperation in Lymphomagenesis
Laura Pasqualucci, MD
3:45 pm Panel Discussion
Session III Faculty
4:00 pm BREAK

SESSION IV
Role of Radiation Therapy
MODERATOR Joachim Yahalom, MD, FACR
4:15 pm Case Presentations
Joachim Yahalom, MD, FACR
4:30 pm When Do I Use Combined Modality Therapy in DLBCL
Paul A. Hamlin, MD
4:45 pm When Do I Use Combined Modality Therapy in Early Stage HL
Marc André, MD
5:00 pm Comining Immune Therapy with Radiation Therapy for Relapsed HL
Craig H. Moskowitz, MD
5:15 pm Panel Discussion
Session IV Faculty, Andreas Engert, MD, John Seymour, MBBS, FRACP, PhD, & Thomas E. Witzig, MD
5:30 pm Networking Cocktail Reception
6:30 pm DAY 1 ADJOURN

SESSION V
Clinical Application of Genome Sequencing
MODERATOR Ahmet Dogan, MD, PhD
8:00 am Introduction to Clinical Diagnostic Genome Sequencing
Maria E. Arcila, MD
8:30 am Genome Sequencing and Outcome of Therapy in DLBCL
Weili Zhao, MD, PhD
8:45 am Genome Sequencing of DLBCL Using Clinical Assays at Memorial Sloan Kettering
Erel Joffe, MD
9:00 am Clinical Application of ctDNA in NHL
Ash A. Alizadeh, MD, PhD
9:15 am Assessment of ctDNA in HL
Davide Rossi, MD, PhD
9:30 am Panel Discussion
Session V Faculty
9:45 am BREAK

SESSION VI
Focus on Precision Medicine: Master Protocol in Lymphoma (MasterLymph)
MODERATOR Anas Younes, MD
10:00 am Genomic Classification of DLBCL, Implications for Precision Medicine
Louis M. Staudt, MD, PhD
10:30 am Biomarker Selection: Targeting EZH2
Franck Morschhauser, MD
10:45 pm Biomarker Selection: Combined HDAC and BCL2 Inhibitors
Connie Lee Batlevi, MD, PhD
11:00 am Biomarker-driven Trials in Lymphoma: Histology-specific or Across Lymphoma Histologies
Thomas E. Witzig, MD
11:15 am Immune Therapy in the Era of Precision Medicine
Ronald Levy, MD
11:30 am Introduction to Lymphoma Master Protocol “MasterLymph”
Anas Younes, MD
11:45 am Panel Discussion
Session VI Faculty
12:15 pm LUNCH

#MSKLYmphomaCME

SATURDAY, MAY 12, 2018

7:30 AM BREAKFAST

SESSION V
Clinical Application of Genome Sequencing
MODERATOR Ahmet Dogan, MD, PhD
8:00 AM Introduction to Clinical Diagnostic Genome Sequencing
Maria E. Arcila, MD
8:30 AM Genome Sequencing and Outcome of Therapy in DLBCL
Weili Zhao, MD, PhD
8:45 AM Genome Sequencing of DLBCL Using Clinical Assays at Memorial Sloan Kettering
Erel Joffe, MD
9:00 AM Clinical Application of ctDNA in NHL
Ash A. Alizadeh, MD, PhD
9:15 AM Assessment of ctDNA in HL
Davide Rossi, MD, PhD
9:30 AM Panel Discussion
Session V Faculty
9:45 AM BREAK

SESSION VI
Focus on Precision Medicine: Master Protocol in Lymphoma (MasterLymph)
MODERATOR Anas Younes, MD
10:00 AM Genomic Classification of DLBCL, Implications for Precision Medicine
Louis M. Staudt, MD, PhD
10:30 AM Biomarker Selection: Targeting EZH2
Franck Morschhauser, MD
10:45 PM Biomarker Selection: Combined HDAC and BCL2 Inhibitors
Connie Lee Batlevi, MD, PhD
11:00 AM Biomarker-driven Trials in Lymphoma: Histology-specific or Across Lymphoma Histologies
Thomas E. Witzig, MD
11:15 AM Immune Therapy in the Era of Precision Medicine
Ronald Levy, MD
11:30 AM Introduction to Lymphoma Master Protocol “MasterLymph”
Anas Younes, MD
11:45 AM Panel Discussion
Session VI Faculty
12:15 PM LUNCH

Myeloma Luncheon (12:15-1:00 PM)*

*Space is limited and RSVP is required during course registration.
SESSION VII
Immune Therapy
MODERATOR: M. Lia Palomba, MD

1:15 PM  CAR T-cell: Transcend Study
David Maloney, MD, PhD

1:30 PM  CAR T-cell: ZUMA-1 Study
Sattva S. Neelapu, MD

1:45 PM  CAR T-cell: Juliet Study
Stephen J. Schuster, MD

2:00 PM  New Approaches
Renier J. Brentjens, MD, PhD

2:15 PM  Immune Checkpoint Inhibitors
Stephen M Ansell, MD, PhD

2:30 PM  Panel Discussion
Session VII Faculty

3:00 PM  BREAK

SESSION VIII
CNS Lymphoma
MODERATOR: Paul A. Hamlin, MD

3:15 PM  How I Treat CNS Lymphoma at the NCI
Wyndham Wilson, MD, PhD

3:30 PM  How I Treat CNS Lymphoma at Memorial Sloan Kettering
Christian Grommes, MD

3:45 PM  Panel Discussion
Session VIII Faculty

4:00 PM  SYMPOSIUM ADJOURN

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>EARLY*</th>
<th>GENERAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs and DOs)</td>
<td>$350</td>
<td>$400</td>
</tr>
<tr>
<td>Nurses, PAs and Other Healthcare Professionals</td>
<td>$150</td>
<td>$200</td>
</tr>
<tr>
<td>Residents and Fellows</td>
<td>$100</td>
<td>$150</td>
</tr>
<tr>
<td>Industry Professionals**</td>
<td>$650</td>
<td>$700</td>
</tr>
</tbody>
</table>

*Early registration available until March 31, 2018

**Industry professionals may attend CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

Register Online:
www.mskcc.org/LymphomaCourse

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary needs.

- **30% Discounted Rate for MSK Alumni and MSK Alliance Members:** MSK offers a 30% discounted rate to all MSK Alumni and MSK Alliance members to attend a CME course. Please contact cme@mskcc.org for a promotion code or more information.
- **MSK Staff Registration:** Registration is complimentary for MSK staff. However, you must register online: www.mskcc.org/LymphomaCourse

ACCREDITATION STATEMENT
MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
MSK designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURE
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use discussed or that the product is still investigational.
MAY 12-13, 2018

This one and half day course will provide a comprehensive review of new entities and challenging areas in the new 2017 WHO Classification of Lymphoid Neoplasms using case-based examples. The course is designed as an interactive slide seminar using microscope based teaching and will be limited to 30 participants.